NovaBridge Biosciences (NBP) Non-Current Deferred Tax Liability (2017 - 2022)

NovaBridge Biosciences (NBP) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $2.5 million in Q4 2022.

• Non-Current Deferred Tax Liability for Q4 2022 came in at $2.5 million, down 10.69% year-over-year; the trailing twelve-month figure through Dec 2022 was $2.5 million (down 10.69% YoY), and the FY2022 annual result was $2.6 million, down 7.93% from the prior year.
• Non-Current Deferred Tax Liability fell to $2.5 million in Q4 2022 per NBP's latest filing, from $2.8 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $5.4 million in Q4 2018 and troughed at $2.5 million in Q4 2022.
• A 3-year average of $3.6 million and a median of $2.8 million in 2021 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2018 and 2022: Non-Current Deferred Tax Liability slipped 4.31% in 2018, then fell 10.69% in 2022.
• A 3-year view of Non-Current Deferred Tax Liability shows it stood at $5.4 million in 2018, then plunged by 47.83% to $2.8 million in 2021, then slipped by 10.69% to $2.5 million in 2022.
• Business Quant data shows NBP's Non-Current Deferred Tax Liability at $2.5 million in Q4 2022, $2.8 million in Q4 2021, and $5.4 million in Q4 2018.